Zynex Medical Electrotherapy Pain Management and Growth Strategy
Adjusted EBITDA
Net Income
Depreciation and Amortization
Stock-based Compensation Expense
Interest Expense and Other (Benefit), net
Income Tax Epense (Benefit)
Adjusted EBITDA
% of Net Revenue
Adjusted EBITDA
Net Income
Depreciation and Amortization
Stock-based Compensation Expense
Interest Expense and Other (Benefit), net
Income Tax Epense (Benefit)
Adjusted EBITDA
% of Net Revenue
EBITDA Reconciliation - 2019
For the Three Months Ended March 31,
2019
2018
Adjusted EBITDA
$
2,350
$
1,921
Net Income
66
25
Depreciation and Amortization
139
63
Stock-based Compensation Expense
(880)
115
Interest Expense and Other (Benefit), net
786
(81)
Income Tax Epense (Benefit)
$
2,461
$
2,043
Adjusted EBITDA
27%
30%
% of Net Revenue
For the Three Months Ended September 30,
2019
2018
Adjusted EBITDA
$
2,033
$
2,591
Net Income
50
59
Depreciation and Amortization
259
76
Stock-based Compensation Expense
0
1
Interest Expense and Other (Benefit), net
463
228
Income Tax Epense (Benefit)
$
2,805
$
2,955
Adjusted EBITDA
24%
36%
% of Net Revenue
For the Three Months Ended June 30,
2019
2018
$
2,162
$
2,418
76
42
158
53
0
37
422
260
$
2,818
$
27%
2,810
37%
2019
For the Three Months Ended December 31,
2018
$
2,947
$
60
2,622
62
264
178
4
0
778
258
$
4,053
$
3,120
29%
33%
ZYNEX
26
MEDICAL"View entire presentation